Clinical Trial Update: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, pharmacokinetics, and efficacy of EDP-305 in non-alcoholic steatohepatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• EDP-305

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: Non-Alcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2021-09-16